Evidence map›Paper›PMID 40703618›Full record

ArticleAsian journal of pharmaceutical sciences2025

Amphiphilic lipid-peptide engineered placenta-derived mesenchymal stem cells for liver fibrosis treatment.

Hee Won Park, Dae Hyun Lee, Sungjun Kim, Hyeri Park, Ashok Kumar Jangid, Chae Eun Lee, Jaewon Park, Gyu Tae Park, Ha Yeon Park, HyunJin Kim and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hee Won ParkDepartment of Chemical & Biochemical Engineering, Dongguk University, Seoul 04620, Republic of Korea.
Dae Hyun LeeDepartment of Biomedical Science, CHA University, Seongnam-si 13488, Gyeonggi-Do, Republic of Korea.
Sungjun KimDepartment of Chemical & Biochemical Engineering, Dongguk University, Seoul 04620, Republic of Korea.
Hyeri ParkDepartment of Biomedical Science, CHA University, Seongnam-si 13488, Gyeonggi-Do, Republic of Korea.
Ashok Kumar JangidDepartment of Chemical & Biochemical Engineering, Dongguk University, Seoul 04620, Republic of Korea.
Chae Eun LeeDepartment of Chemical & Biochemical Engineering, Dongguk University, Seoul 04620, Republic of Korea.
Jaewon ParkDepartment of Chemical & Biochemical Engineering, Dongguk University, Seoul 04620, Republic of Korea.
Gyu Tae ParkDepartment of Physiology, College of Medicine, Pusan National University, Yangsan 50612, Gyeongsangnam-do, Republic of Korea.
Ha Yeon ParkDepartment of Biological Sciences and Bioengineering, Inha University, Incheon 22212, Republic of Korea.
HyunJin KimDepartment of Biological Sciences and Bioengineering, Inha University, Incheon 22212, Republic of Korea.
Jae Ho KimDepartment of Physiology, College of Medicine, Pusan National University, Yangsan 50612, Gyeongsangnam-do, Republic of Korea.
Gi Jin KimDepartment of Biomedical Science, CHA University, Seongnam-si 13488, Gyeonggi-Do, Republic of Korea.
Kyobum KimDepartment of Chemical & Biochemical Engineering, Dongguk University, Seoul 04620, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global mortality rate due to liver diseases, particularly liver fibrosis, is increasing. Among various treatment methods, stem cell therapy using placenta-derived mesenchymal stem cells (PDMSCs) offers distinct benefits, including ease of isolation and superior proliferative potential. To enhance the therapeutic efficacy of PDMSCs, the WKYMVm peptide was selected for cell engineering. Immobilization of WKYMVm on PDMSC membranes facilitates effective peptide binding to the formyl peptide receptor 2 on adjacent PDMSCs and hepatocytes, thereby enhancing cell activation and achieving more efficient peptide utilization compared to bolus peptide treatment. Increased cell activation enhances the secretion of paracrine factors including growth factors and cytokines, which in turn improves liver function and vascular repair in both

Indexed as

Acute liver treatmentAngiogenesisBiomaterial-mediated cell surface engineeringLipid-peptide conjugatesPeptide engineeringStem cell therapy

Identifiers

PMID40703618
PMCPMC12281255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.